Company intelligence / Profile preview
Tianjin Hemay Biotech
Tianjin Airport Economic Zone, Tianjin, Chinahemay.com.cn ↗
- Ownership
- Private
- Development stage
- Phase 2
01
Overview
The company has several small molecule drugs in clinical development targeting autoimmune diseases and cancers. Lead asset Mufemilast has reached Phase III for plaque psoriasis and Behçet's syndrome; other assets are in various stages up to Phase III for oncology and immunology indications. Multiple patents granted globally.
- Therapeutic areas
- OncologyImmunologyDermatologyRheumatologyGastroenterology
- Modalities
- Small molecules
- Industry
- Biotech
02
Drug pipeline
9 assets8 more assets in the full pipeline.
03
Partnerships
Hainan HailingGanzhou Hemay PharmaceuticalXiajiang Hemei Pharmaceutical Co.Hainan General Sanyang Pharmaceutical Co.academic/government collaborations via national science projects.
Beyond the preview
Go deeper on Tianjin Hemay Biotech.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Tianjin Hemay Biotech.